WallStSmart

Boston Scientific Corp (BSX)vsPulmonx Corp (LUNG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 23181% more annual revenue ($20.61B vs $88.55M). BSX leads profitability with a 17.3% profit margin vs -60.1%. BSX earns a higher WallStSmart Score of 76/100 (B+).

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 6.3
Piotroski: 5/9

LUNG

Avoid

34

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: -5.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-29.4%)

Margin of Safety

-29.4%

Fair Value

$37.35

Current Price

$48.55

$11.20 premium

UndervaluedFair: $37.35Overvalued

Intrinsic value data unavailable for LUNG.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$70.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.588/10

Growing faster than its price suggests

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

LUNG1 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

LUNG4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$64.62M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.233/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : LUNG

The strongest argument for LUNG centers on Price/Book.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : LUNG

The primary concerns for LUNG are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

BSX profiles as a mature stock while LUNG is a turnaround play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.62 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 34/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Pulmonx Corp

HEALTHCARE · MEDICAL DEVICES · USA

Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?